Fennec grants 50,000 inducement stock options to three new employees at $9.75 per share
Fennec Pharmaceuticals granted stock options to purchase 50,000 common shares to three new non-executive employees under its 2026 Equity Inducement Plan, with a grant date of May 18, 2026. The options have an exercise price of $9.75 per share and vest over three years, and the filing describes them as inducement awards under Nasdaq Listing Rule 5635(c)(4) for new hires, with no financial effect reported.
Key points
- Options cover an aggregate of 50,000 common shares granted to three new non-executive employees
- Exercise price is $9.75 per share, equal to the closing price on March 15, 2026, with a ten-year term
- One-third vests on the one-year anniversary of the May 18, 2026 grant date, then monthly over the following 24 months
- Grants include 49,141 incentive stock options and 859 nonqualified stock options
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 18, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.